Ozi ndị ọzọ ― Igbo

Urticarial vasculitis bụ ọnọdụ a na-adịghị ahụkebe nke akara hives na-adịte aka ma ọ bụ ugboro ugboro. Ọ bụ ezie na mgbaàmà akpụkpọ ahụ ya nwere ike ịdị ka hives na-adịghị ada, ha pụrụ iche n'ihi na hives na-anọ n'ahụ ruo awa 24 ma nwee ike ịhapụ ntụpọ ojii mgbe ha dara. Ọ bụ ezie na a ka na-amaghị ihe kpatara ya, ụfọdụ ọgwụ, ọrịa na-efe efe, ọrịa autoimmune, ọrịa ọbara, ma ọ bụ ọrịa cancer nwere ike ịkpalite ya. Ụfọdụ ọmụmụ ejikọtala ya na ọrịa COVID-19 na H1N1. Ọ nwekwara ike imetụta akụkụ ahụ ndị ọzọ dịka mọzụlụ, akụrụ, ngụgụ, afọ, na anya. Ọ bụ ezie na ụfọdụ ụdị nyocha anụ ahụ nwere ike ịkwado nchọpụta ahụ, ọ bụghị mgbe niile ka ọ dị mkpa. Ọgwụgwọ na-amalitekarị site na ọgwụ nje, dapsone, colchicine, ma ọ bụ hydroxychloroquine maka ndị dị nro. Maka ikpe ndị ka njọ, ọgwụ ndị na-egbochi usoro ahụ ji alụso ọrịa ọgụ dịka methotrexate ma ọ bụ corticosteroids nwere ike ịdị mkpa. Na nso nso a, usoro ọgwụgwọ ndu (rituximab, omalizumab, interleukin-1 inhibitors) egosila nkwa maka ikpe siri ike.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.

Otu nwoke dị afọ 35 batara na akụkọ ihe mere eme nke ụbọchị iri na ise nke na-acha uhie uhie na-egbuke egbuke, na-egbu mgbu na apata ụkwụ na ụkwụ, yana mgbu nkwonkwo. O nwere ọrịa urinary tract otu izu tupu ọkụ ọkụ apụta. Akpụkpọ ahụ ya gosiri ọtụtụ ihe dị nro, yiri mgbanaka, nke na-acha uhie uhie, n'akụkụ abụọ nke apata ụkwụ ya na ụkwụ ya. E nyere ya prednisolone ọnụ (40 mg/ụbọchị) maka otu izu yana ọgwụ antihistamine na-adịghị ehi ụra (fexofenadine). N'ime otu izu, rashes niile kwụsịrị kpamkpam. Enwekwaghị ọkụ ọkụ ọzọ n'ime ọnwa isii na-esote nke nyocha oge niile.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.